A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.

Abstract

5009 Background: Ovarian cancer (OC) has the highest mortality of all cancers involving the female genital tract. Platinum-based therapy is standard primary treatment. Treatments to extend survival, while preserving quality of life, are needed for platinum-resistant patients where current treatment options yield < 4 months progression free survival (PFS) and < 10 months overall survival (OS). This study evaluates the combination of nab-paclitaxel (Abraxane) with bevacizumab in platinum-resistant patients. Methods: 48 patients who had recurrent platinum-resistant OC (93.7%) or primary peritoneal carcinoma with measurable disease (by CT/MRI) were enrolled. 19 (40%) patients had one prior regimen, 27 (56%) had two prior regimens, and 2 (4%) patients had more than two prior regimens. All patients received nab-paclitaxel 100 mg/m2 IV on days 1, 8, 15 with bevacizumab 10 mg/kg IV given on days 1 and 15 every 28 days, and were treated until progression. Results: Mean age was 61 (range 38-87 years) and patients w...